ConductScience.org, home

Paper36906936

Pharmacokinetic and pharmacodynamic considerations for treating sarcoptic mange with cross-relevance to Australian wildlife.

Takano K and 4 others. Int J Parasitol Drugs Drug Resist, 2023. Cited by 11 papers, by iCite.

Cite this record

ConductScience Library. Pharmacokinetic and pharmacodynamic considerations for treating sarcoptic mange with cross-relevance to Australian wildlife. Papers, record 36906936. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36906936

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmacokinetic and pharmacodynamic considerations for treating sarcoptic mange with cross-relevance to Australian wildlife.
PubMed
Journal
Int J Parasitol Drugs Drug Resist
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
11
iCite
Relative citation ratio, by iCite
2.42
iCite
Revised in PubMed
2024-09-14
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Takano KKotaro
2de Hayr LLachlan
3Carver SScott
4Harvey RJRobert J
5Mounsey KEKate E

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ScabiesMajor topic
AcaricidesMajor topic
Animals
Humans
Animals, Wild
Australia
Sarcoptes scabiei
Mammals

Source PubMed

Download CSV of topics

References240

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133720993Two novel loci underlie natural differences in Caenorhabditis elegans abamectin responses.PLoS Pathog2021https://conductscience.org/library/papers/33720993PubMed
227012161Efficacy of oral afoxolaner for the treatment of canine generalised demodicosis.Parasite2016https://conductscience.org/library/papers/27012161PubMed
315463742Ivermectin resistance.Parasitol Today1993https://conductscience.org/library/papers/15463742PubMed
434309214Frequencies and mechanisms of pesticide resistance in Tetranychus urticae field populations in China.Insect Sci2022https://conductscience.org/library/papers/34309214PubMed
530025642The role of glutathione S-transferases (GSTs) in insecticide resistance in crop pests and disease vectors.Curr Opin Insect Sci2018https://conductscience.org/library/papers/30025642PubMed
617851096The pharmacokinetics and metabolism of ivermectin in domestic animal species.Vet J2009https://conductscience.org/library/papers/17851096PubMed
735155125Intravenous veterinary ivermectin in a COVID-19 patient causing neurotoxicity.IDCases2022https://conductscience.org/library/papers/35155125PubMed
810716995The genetics of ivermectin resistance in Caenorhabditis elegans.Proc Natl Acad Sci U S A2000https://conductscience.org/library/papers/10716995PubMed
917004957Clinical presentation and management of moxidectin toxicity in two dogs.J Small Anim Pract2006https://conductscience.org/library/papers/17004957PubMed
1033407820Fluralaner as a novel treatment for sarcoptic mange in the bare-nosed wombat (Vombatus ursinus): safety, pharmacokinetics, efficacy and practicable use.Parasit Vectors2021https://conductscience.org/library/papers/33407820PubMed
117082235The use of amitraz in the control of an outbreak of sarcoptic mange in a colony of koalas.Aust Vet J1982https://conductscience.org/library/papers/7082235PubMed
1229089046The novel isoxazoline ectoparasiticide lotilaner (Credelio™): a non-competitive antagonist specific to invertebrates γ-aminobutyric acid-gated chloride channels (GABACls).Parasit Vectors2017https://conductscience.org/library/papers/29089046PubMed
1314635176Chloride channels as tools for developing selective insecticides.Arch Insect Biochem Physiol2003https://conductscience.org/library/papers/14635176PubMed
1418335094Outcomes of the California ban on pharmaceutical lindane: clinical and ecologic impacts.Environ Health Perspect2008https://conductscience.org/library/papers/18335094PubMed
1527732588Preclinical Study of Single-Dose Moxidectin, a New Oral Treatment for Scabies: Efficacy, Safety, and Pharmacokinetics Compared to Two-Dose Ivermectin in a Porcine Model.PLoS Negl Trop Dis2016https://conductscience.org/library/papers/27732588PubMed
1612359484Breed differences on the plasma availability of moxidectin administered pour-on to calves.Vet J2002https://conductscience.org/library/papers/12359484PubMed
1711714703Identification of two novel Drosophila melanogaster histamine-gated chloride channel subunits expressed in the eye.J Biol Chem2002https://conductscience.org/library/papers/11714703PubMed
189154544Success of a scabies control program in an Australian aboriginal community.Pediatr Infect Dis J1997https://conductscience.org/library/papers/9154544PubMed
1915135868Dermal safety study with imidacloprid/moxidectin topical solution in the ivermectin-sensitive collie.Vet Parasitol2004https://conductscience.org/library/papers/15135868PubMed
2015206075First documentation of in vivo and in vitro ivermectin resistance in Sarcoptes scabiei.Clin Infect Dis2004https://conductscience.org/library/papers/15206075PubMed

See all 240 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.

PMIDTitleJournalYearIn PapersSource
42093003
Selection of the optimal long-acting injectable formulation of ivermectin for use in humans to target malaria vectors in Western Africa: evaluation of pharmacokinetics and mosquitocidal efficacy in cattle under laboratory conditions.
Parasit Vectors2026https://conductscience.org/library/papers/42093003PubMed
40225591Pharmacokinetics and safety of topical fluralaner in koalas (Phascolarctos cinereus ).Int J Parasitol Parasites Wildl2024https://conductscience.org/library/papers/40225591PubMed
39109221Ivermectin therapy for young children with scabies infection: a multicentre phase 2 non-randomized trial.Lancet Reg Health West Pac2024https://conductscience.org/library/papers/39109221PubMed
39010037Global prevalence and predictors of scabies among prisoners: systematic review and meta-analysis.BMC Public Health2024https://conductscience.org/library/papers/39010037PubMed
38664829Assessment of the in vitro acaricidal activity of Bravecto® (fluralaner) and a proposed orange oil-based formulation vehicle for the treatment of Sarcoptes scabiei.Parasit Vectors2024https://conductscience.org/library/papers/38664829PubMed
38433167Scabies: Immunopathogenesis and pathological changes.Parasitol Res2024https://conductscience.org/library/papers/38433167PubMed
37656230Evaluation of the scabicidal effect of a single dose of fluralaner in a rabbit model of crusted scabies.Parasitol Res2023https://conductscience.org/library/papers/37656230PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABCB15243PubTator's text mininghttps://conductscience.org/library/genes/5243NCBI Gene
PGP283871PubTator's text mininghttps://conductscience.org/library/genes/283871NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36906936

GET https://conductscience.org/api/papers/v1/36906936/references?page=2